Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsGloria Huang, MD, FACOG
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Biography
Gloria Huang, MD, is an internationally known expert in the treatment and prevention of ovarian, uterine and cervical cancers. Dr. Huang is skilled at minimally invasive surgery and is the principal investigator of a federally-funded cancer research laboratory. A board-certified gynecologic oncologist, Dr. Huang enjoys providing exceptional, individualized, comprehensive care to patients, bringing together multi-disciplinary clinical teams to achieve the best outcomes. She is passionate about advancing the field of gynecologic oncology through innovative scientific research and hopes her discoveries will lead to better treatments for patients. Watch a video with Dr. Gloria Huang >>
Last Updated on May 01, 2025.
Departments & Organizations
- Discovery to Cure Internship
- Genomics, Genetics, and Epigenetics
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Oligometastatic Cancer Program
- Yale Cancer Center
Education & Training
- Gynecologic Oncology Fellowship
- Albert Einstein College of Medicine (2005)
- Postdoctoral Fellowship
- Stanford University School of Medicine (2002)
- Residency
- Stanford University School of Medicine (2001)
- MD
- Stanford University School of Medicine (1997)
- BS
- Yale University, Biology (1992)
Research
Copy Link
Overview
Endometriosis-associated ovarian cancer
Medical Research Interests
Endometrial Neoplasms; Genital Neoplasms, Female; Genomics; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Pelvic Neoplasms; Uterine Neoplasms
ORCID
0000-0002-0001-888X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Gloria Huang's published research.
Publications Timeline
A big-picture view of Gloria Huang's research output by year.
Research Interests
Research topics Gloria Huang is interested in exploring.
Alessandro Santin, MD
Pei Hui, PhD, MD
Peter Schwartz
Former YSMMasoud Azodi, MD
Natalia Buza, MD
Mitchell Clark, MD, MPH
82Publications
2,949Citations
Uterine Neoplasms
Ovarian Neoplasms
Endometrial Neoplasms
Genital Neoplasms, Female
Neoplasm Metastasis
Pelvic Neoplasms
Publications
2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchCitationsRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchARID1A in Gynecologic Precancers and Cancers
Morgan J, Jaferi N, Shonibare Z, Huang G. ARID1A in Gynecologic Precancers and Cancers. Reproductive Sciences 2024, 31: 2150-2162. PMID: 38740655, DOI: 10.1007/s43032-024-01585-w.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchCitationsAltmetricCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Commentaries, Editorials and LettersCitationsAltmetric
2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, PMCID: PMC12626252, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchCitationsAltmetricHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricUterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.Peer-Reviewed Original ResearchCitationsAltmetricThe Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa S, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.Peer-Reviewed Original ResearchCitationsTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.Peer-Reviewed Original ResearchCitations
Academic Achievements & Community Involvement
Copy Link
Activities
activity NRG Oncology
2018 - PresentProfessional OrganizationsCommittee MemberDetailsGYN Rare Tumor Subcommittee Core Memberactivity Discovery to Cure Internship
2018 - PresentPublic ServiceMentorDetailsResearch mentorship program for high school studentsactivity Committee on the Status of Women in Medicine
2021 - PresentCommitteesExecutive Board Memberactivity Reproductive Sciences
2021 - PresentJournal ServiceAssociate Editoractivity Frontiers in Oncology
2021 - PresentJournal ServiceAssociate Editor
Honors
honor Blavatnik Fund for Innovation Award
06/01/2022Yale University AwardBlavatnik Family Foundation, Yale Ventureshonor Fellow
01/01/2020National AwardAmerican Gynecological and Obstetrical Societyhonor DOD Ovarian Cancer Research Program Pilot Award
09/01/2016National AwardDepartment of Defense Congressionally Mediated Medical Research ProgramDetailsUnited Stateshonor Reproductive Scientist Development Program Seed Award
07/01/2014National AwardRSDPDetailsUnited Stateshonor American Association of Obstetricians and Gynecologists Bridge Award
07/01/2014National AwardAAOGFDetailsUnited States
News
Copy Link